Loading SYK detail
Loading ticker data...
Loading SYK detail
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine.
The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries.
Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Chart data unavailable
CCLA Investment Management grew its stake in shares of Stryker Corporation (NYSE: SYK) by 4.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 401,936 shares of the medical technology company's stock after buying an additional 17,778 shares during the quarter.
Allspring Global Investments Holdings LLC decreased its holdings in Stryker Corporation (NYSE: SYK) by 32.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,408 shares of the medical technology company's stock after selling 7,373 shares during the quarter. Allspring Global Investments
Runnymede Capital Advisors Inc. bought a new position in shares of Stryker Corporation (NYSE: SYK) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,255 shares of the medical technology company's stock, valued at approximately $3,253,000. Stryker comprises about 1.9% of Runnymede Capital Advisors
Savvy Advisors Inc. increased its position in shares of Stryker Corporation (NYSE: SYK) by 81.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,630 shares of the medical technology company's stock after acquiring an additional 2,523 shares during the period. Savvy Advisors
IM Cannabis (NASDAQ: IMCC - Get Free Report) and Stryker (NYSE: SYK - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Profitability This table compares IM Cannabis and Stryker's net
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2026.
Portage, Michigan, March 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today Nick Mead has been appointed Vice President, Investor Relations, effective May 1, 2026. Mead has nearly 20 years of experience at Stryker, with leadership roles spanning multiple divisions and business units across the company.
Beacon Investment Advisory Services Inc. lessened its holdings in Stryker Corporation (NYSE: SYK) by 4.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 60,194 shares of the medical technology company's stock after selling 2,520 shares during the period. Beacon Investment Advisory Services Inc.'s holdings
Chesley Taft and Associates LLC raised its holdings in Stryker Corporation (NYSE: SYK) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141,083 shares of the medical technology company's stock after purchasing an additional 3,230 shares during the quarter. Stryker
Bonness Enterprises Inc. lessened its stake in Stryker Corporation (NYSE: SYK) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,939 shares of the medical technology company's stock after selling 1,550 shares during the period. Stryker comprises
Medical device maker Stryker said on Thursday its operations were steadily improving towards full capacity, after a cyberattack caused widespread disruption to its business.
Czech National Bank boosted its position in Stryker Corporation (NYSE: SYK) by 3.9% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 90,755 shares of the medical technology company's stock after acquiring an additional 3,366 shares during the period. Czech National Bank's holdings in Stryker were
DAVENPORT and Co LLC raised its position in shares of Stryker Corporation (NYSE: SYK) by 19.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,149 shares of the medical technology company's stock after purchasing an additional 4,896 shares
Stryker Corporation (NYSE: SYK - Get Free Report) has received an average rating of "Moderate Buy" from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target
